Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway. NJPS [Internet]. 2025 Dec. 31 [cited 2026 Apr. 14];40(2):251-62. Available from: https://www.ojshostng.com/index.php/njphysiologicalsciences/article/view/4001